NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Welcome to the board! In her May 15, 2012 interview, Linda Powers was thinking 37K per year for three years (see below) (This would vary from country to country). I agree with you that penetration and saturation is critical. There was some manufacturing report quite a ways back where Cognate came up with a more cost effective manufacturing process. More importantly, here is what Linda Powers had to say on pricing, costs and the like in a May 15, 2012 interview.

Well, with these therapies, the healthcare system would not be paying for a hundred percent of patients to take a drug when only twenty-five percent of them get any effect of it [Because DCVAX-L has over an 80% response rate]. Secondly, the healthcare system would be getting a lot of bang for their buck with years of extended survival instead of two months of extended survival.

We plan to charge approximately in the range of thirty-seven thousand dollars a year per year of a three year treatment regimen, so about a hundred and ten thousand dollars for all three years combined, and with that we can still produce very nice EBITA (Earnings Before Interest, Taxes and Amortization) margins for our investors. As you know, that’s way below the pricing matrix. I mean Avastin is typically sixty to eighty thousand a year. Even all standbys like Temodar are fifty, sixty thousand a year.

JE: So you see the healthcare companies falling behind this once you have successful clinical trials and the product has come to market?

LP: We really do because of huge cost effectiveness and because of one more thing I haven’t mentioned to you, which is simplicity, absolute simplicity. The finished product is loaded in a standard syringe that every clinic on the planet has and it’s administered intradermal, under the skin, as a shot in the arm, like a flu shot or an insulin shot. That’s it. No three and four hour infusion of toxic chemo or even a three or four hour infusion of immune therapy. It’s a shot in the arm under the skin, that can be administered anywhere. Not just in these centers of excellence – which are great – but is not where ninety plus percent of the cancer patients get their treatment. They get their treatment in regular doctors’ offices and community hospitals, and so we’re positioning this to become a new standard of care and it has, we believe, the profile to make that possible. It has the clinical effectiveness. It has the cost effectiveness and it has the simplicity.

http://www.blackandwhiteprogram.com/interview/northwest-biotherapeutics-inc-nwbo-ob-interview-with-linda-f-powers-ceo